Blend Vial strength 10mg Blend
Tesamorelin 5mg + Ipamorelin 5mg10mg Blend
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Tesamorelin 5mg + Ipamorelin 5mg, explained simply
A blend pairing GHRH signalling with the ghrelin pathway; a rationale does not establish the effects of the mixture itself.
Research area
Growth hormone axis
How it works
This blend combines a GHRH analogue, tesamorelin, with a ghrelin-pathway secretagogue, ipamorelin.
Why it matters
It allows comparison of two signals that converge on growth hormone release.
What has been observed
The blend's rationale comes from mechanisms and evidence on the two components considered separately.
Effects and points to consider
Evidence for tesamorelin alone does not establish efficacy or safety for the equal-parts mixture.
01 / Vial strength 10mg Blend
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Total vial mass | 10 mg |
|---|---|
| Component masses | Tesamorelin: 5 mg; Ipamorelin: 5 mg |
| Final volume | 3 mL |
| Concentration | 3.33 mg/mL |
| Frequency | once daily |
| Cycle | 16 in table |
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Tesamorelin Dose | Ipamorelin Dose | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 125 mcg (0.125 mg) | 23 units (0.23 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 250 mcg (0.25 mg) | 45 units (0.45 mL) |
| Weeks 5–6 | 1000 mcg (1.0 mg) | 500 mcg (0.5 mg) | 90 units (0.90 mL) |
| Weeks 7–10 | 1500 mcg (1.5 mg) | 750 mcg (0.75 mg) | 135 units (1.35 mL) |
| Weeks 11–16 | 2000 mcg (2.0 mg) | 1000 mcg (1.0 mg) | 180 units (1.80 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.